Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors

• Published in: European journal of medicinal chemistry Vol. 230; p. 114106
• Main Authors: Tang, Kai, Zhao, Min, Wu, Ya-Hong, Wu, Qiong, Wang, Shu, Dong, Yu, Yu, Bin, Song, Yihui, Liu, Hong-Min
• Format: Journal Article
• Language: English
• Published: ISSY-LES-MOULINEAUX Elsevier Masson SAS 15.02.2022; Elsevier
• Subjects: Allosteric Site; Aminopyrazines; Chemistry, Medicinal; Dephosphorylase; Enzyme Inhibitors - pharmacology; HeLa Cells; Humans; Life Sciences & Biomedicine; Pharmacology & Pharmacy; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 11 - antagonists & inhibitors; Pyrazines - pharmacology; Science & Technology; SHP2 inhibitor; Structure-Activity Relationship; JMML; ΔTm; B-ALL; TSA; NS; PROTAC; SSG; DIPEA; LS; SARs; AKT; TLC; PTP; TFA; Aminopyrazines; NMP; HRMS; MEK; PI3K; Dephosphorylase; Tm; TMS; SHP2 inhibitor; Erk; RAS; GROWTH; PTPN11; TYROSINE-PHOSPHATASE SHP2; MUTATIONS; IDENTIFICATION; DISCOVERY
• ISSN: 0223-5234; 1768-3254
• DOI: 10.1016/j.ejmech.2022.114106

Src homology-2-containing protein tyrosine phosphatase 2 (SHP2) encoded by the proto-oncogene PTPN11 is the first identified non-receptor protein tyrosine phosphatase. SHP2 dysregulation contributes to the pathogenesis of different cancers, making SHP2 a promising therapeutic target for cancer therapy. In this article, we report the structure-guided design based on the well-characterized SHP2 inhibitor SHP099, extensive structure-activity relationship studies (SARs) of aminopyrazines, biochemical characterization and cellular potency. These medicinal chemistry efforts lead to the discovery of the lead compound TK-453, which potently inhibits SHP2 (SHP2WT IC50 = 0.023 μM, ΔTm = 7.01 °C) in a reversible and noncompetitive manner. TK-453 exhibits high selectivity over SHP2PTP, SHP1 and PTP1B, and may bind at the “tunnel” allosteric site of SHP2 as SHP099. As the key pharmacophore, the aminopyrazine scaffold not only reorganizes the cationic-π stacking interaction with R111 via the novel hydrogen bond interaction between the S atom of thioether linker and T219, but also mediates a hydrogen bond with E250. In vitro studies indicate that TK-453 inhibits proliferation of HeLa, KYSE-70 and THP-1 cells moderately and induces apoptosis of Hela cells. Further mechanistic studies suggest that TK-453 can decrease the phosphorylation levels of AKT and Erk1/2 in HeLa and KYSE-70 cells. Collectively, TK-453 is a highly potent, selective, and cellularly active allosteric SHP2 inhibitor that modulates the phosphorylation of SHP2-mediated AKT and Erk cell signaling pathways by inhibiting the phosphatase activity of SHP2. [Display omitted] •48 aminopyrazine derivatives were synthesized and evaluated inhibitory activity against SHP2.•TK-453 is a highly potent, selective, and cellularly active allosteric SHP2 inhibitor.•TK-453 can modulate the phosphorylation of SHP2-mediated AKT and Erk cell signaling pathways.